The double treatment also strongly decreased the number of TAM displaying the M2 marker CD206, which heavily infiltrate 3-MCA sarcoma from untreated mice, whereas the few CD86+ TAM present were unaffected by the therapy. This evidence concerns the gene MRC1 and sarcoma.